Clinical trials: Myeloid
Relapsed/Refractory AML
Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients
This study will evaluate the safety and tolerability of uproleselan(GMI-1271), a specific E-selectin antagonist, and characterize the pharmacokinetic (PK) profile of uproleselan, in combination with chemotherapy to treat Chinese…
- Trial name
- NCT04839341
- Testing
- Uproleselan
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- Apollomics Inc.
Chronic Myeloproliferative Disorders, Fever, Sweats, and Hot Flashes
Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer
RATIONALE: Antibiotics such as amoxicillin, ciprofloxacin, and moxifloxacin may be effective in preventing or controlling fever and neutropenia in patients with cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Fever, Sweats, and Hot Flashes, Infection, Leukemia
- Trial name
- NCT00062231
- Testing
- amoxicillin-clavulanate potassium, ciprofloxacin, moxifloxacin hydrochloride
- Where
- 23 sites in Belgium, France and 6 more
- Volunteers
- 351 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Acute Myeloid Leukemia, Adult
A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML
This is a multi-center open clinical study aimed at evaluating the efficacy and safety of Clifutinib Besylate combined with chemotherapy in newly-treated adult subjects with AML
- Trial name
- NCT05133882
- Testing
- Clifutinib Besylate
- Where
- China
- Volunteers
- 133 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Acute Myeloid Leukemia
Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML
To evaluate the safety and tolerability of RC1012 infusion in patients with relapsed or refractory Acute Myelocytic Leukemia (r/r AML).
- Trial name
- NCT05471323
- Testing
- RC1012 injection (allo-DNT cells)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Guangdong Ruishun Biotech Co., Ltd
Leukemia, Lymphoma
Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation
RATIONALE: Giving low-dose total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00996359
- Testing
- Irradiated haploidentical allogeneic lymphocytes, total-body irradiation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Acute Myeloid Leukemia
DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML
For several years, the effective standard induction chemotherapy for AML has been limited to the association of anthracycline and aracytine. GO is the first effective targeted antibody used in leukemia patients.
- Trial name
- MYLOFRANCE2 (NCT02182596)
- Testing
- Mylotarg
- Where
- 15 sites in France
- Volunteers
- 20 people
- Sponsor
- Acute Leukemia French Association
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia
This randomized phase I trial is studying the side effects and best dose of two different schedules of sorafenib in treating patients with refractory or relapsed acute leukemia, myelodysplastic syndromes, or blastic phase chronic…
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia
- Trial name
- NCT00217646
- Testing
- Sorafenib Tosylate
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia (AML)
Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
This open label, multicenter phase II/III study with multiple randomization phases at differents stages of AML treatment (induction, consolidation and HSCT where applicable) is designed to improve OS in younger (18 to 60…
- Trial name
- BIG-1 (NCT02416388)
- Testing
- Idarubicin, Daunorubicin, HD Cytarabine
- Where
- 56 sites in France
- Volunteers
- 3,100 people
- Sponsor
- University Hospital, Angers
Chronic Myeloid Leukemia
A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients
This study is to evaluate efficacy and safety of Imatinib in two groups of patients; all patients should be diagnosed less than 3 months as chronic myeloid leukemia in a chronic phase.
- Trial name
- IDEAL (NCT02204722)
- Testing
- 600mg/day of Imatinib, 400mg/day of Imatinib
- Where
- South Korea
- Volunteers
- 55 people
- Sponsor
- Dong-A ST Co., Ltd.
Leukemia
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
The purpose of the study is to compare response rates in newly diagnosed Chronic Phase (CP) CML subjects treated with dasatinib plus BMS-833923 versus dasatinib alone.
- Trial name
- NCT01357655
- Testing
- Dasatinib, BMS-833923
- Where
- 24 sites in United States, Argentina and 6 more
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia
Occupational Status and Hematological Disease
Diseases do not only have a physical role in people's live, but they usually involve changes in life as whole. They may modify the structure of the conjunction with life setting, thus, deeply impacting relationships with others.
- Conditions
- Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndrome, Chronic Thrombocytopenia
- Trial name
- EMATO0113 (NCT02057185)
- Testing
- Study questionnaire, SF-36 Questionnaire
- Where
- 6 sites in Italy
- Volunteers
- 141 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Myeloid Diseases
Austrian Myeloid Registry
The Austrian Myeloid Registry (aMYELOIDr) is a non-interventional study. It collects data from patients with the myeloid diseases, primarily myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute…
- Trial name
- aMYELOIDr (NCT04438889)
- Testing
- Non-interventional
- Where
- 16 sites in Austria
- Volunteers
- 3,000 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
This phase I trial studies the side effects and the best dose of trebananib when given together with or without low-dose cytarabine in treating patients with acute myeloid leukemia (AML).
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT01555268
- Testing
- trebananib, cytarabine, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Roswell Park Cancer Institute
Advanced Solid Tumors, Acute Myeloid Leukaemia (AML)
RVU120 Rollover Study
This is a multicenter rollover study to provide continued treatment to eligible participants previously enrolled in a RVU120 clinical study and to evaluate the safety of the treatment and record the time on treatment when…
- Conditions
- Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic Syndrome
- Trial name
- ROVER-01 (NCT06987058)
- Testing
- RVU120, Ruxolitinib
- Where
- 7 sites in France, Poland
- Volunteers
- 14 people
- Sponsor
- Ryvu Therapeutics SA
AML, MRD
Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results
This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor in combination with azacitidine and venetoclax for untreated acute myeloid leukemia based on MRD results on day 14 of…
- Trial name
- AVS (NCT05736978)
- Testing
- Azacitidine, Venetoclax, Selinexor
- Where
- 4 sites in China
- Volunteers
- 58 people
- Sponsor
- Shanghai Tong Ren Hospital
Acute Myeloid Leukemia (AML)
Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AML
This prospective, open-label, multicenter phase Ib trial will evaluate the safety, tolerability, and RP2D of the VAM regimen (liposomal mitoxantrone + azacitidine [AZA] + venetoclax [VEN]) in elderly or unfit patients with newly…
- Trial name
- NCT07828535
- Testing
- Liposome Mitoxantrone, Venetoclax, Azacitidine
- Volunteers
- 30 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia
Role of PTK-7 in Acute Myeloid Leukemias
The pseudo tyrosine kinase receptor 7 (PTK7) is an orphan tyrosine kinase receptor assigned to the planar cell polarity pathway. PTK7 is expressed in normal myeloid progenitors and CD34(+) CD38(-) bone marrow cells in humans.
- Trial name
- LAM-PTK7 (NCT02860793)
- Testing
- Bone marrow aspiration, Blood sampling
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Institut Paoli-Calmettes
Acute Myeloid Leukemia
Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia
The purpose of this study is to determine the safety, efficacy and pharmacokinetics of mitoxantrone hydrochloride liposome injection combined with chemotherapy in previously untreated de novo acute myeloid leukemia.
- Trial name
- NCT05941585
- Testing
- Mitoxantrone hydrochloride liposome injection30mg/m2, HomoharringtonineD1-D7(2mg/m2/day), Venetoclax (d4 100mg/day, d5200mg/day ,d6-d12 400mg/day)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Leukemia, Myelodysplastic Syndromes
Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia
RATIONALE: Drugs used in chemotherapy, such as clofarabine, cytarabine, and idarubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- AML-14A (NCT00838240)
- Testing
- clofarabine, cytarabine, idarubicin
- Where
- 10 sites in Belgium, Croatia and 3 more
- Volunteers
- 114 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
This phase I trial tests the safety, side effects, and best dose of a new 8-chloroadenosine in combination with venetoclax in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to…
- Conditions
- Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT05263284
- Testing
- 8-Chloroadenosine, Venetoclax
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.